Results 201 to 210 of about 455,243 (269)

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

SMARTCLOTH Prototype for Dietary Management in Patients With Diabetes Mellitus: Tutorial on Human-Centered Design Methodology for Health Care Hardware Development.

J Med Internet Res
Palomares JM, Molina-Luque R, León-García F, Casares-Rodríguez I, García-Rodríguez M, Villena Esponera MP, Molina-Recio G.   +6 more
europepmc   +1 more source

Clinician Communication and Patient Safety in Pediatrics: A Practical Application of Human-Centered Design for Problem Identification and Analysis. [PDF]

J Patient Saf
Ruppel H, Luo B, Won J, Bonafide CP, Albanowski K, DeChalus A, Reed B, Khan AN, Tomlinson AZ, Fu A, Ettore J, Leary M.   +11 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Streamlining Patient Fall Prevention and Management Through Human-Centered AI-Based Decision Support Systems. [PDF]

Risk Manag Healthc Policy
Rahmadani F, Alshamsi FY, Almazrouei B, Hanaya Alsuwaidi A, Alhammadi M, Simsekler MCE.   +5 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Designing Patient-Friendly Messages: Tutorial on Applying Human-Centered, Self-Determination Theory With AI Considerations.

J Med Internet Res
Griffin AC, Javier SJ, Golding M, Runnels TW, Matthias MS, Shimada SL, Higgins DM, Zulman DM, Midboe AM.   +8 more
europepmc   +1 more source

Leveraging community engagement and human-centered design to develop multilevel implementation strategies to enhance adoption of a health equity intervention. [PDF]

Implement Sci Commun
Price MA, Mulkern PJ, Condon M, Rakhilin M, Johansen K, Lyon AR, Saldana L, Pachankis J, Woodward SA, Roeder KM, Moran LR, Jerskey BA.   +11 more
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

How to Improve Pancreatic Cancer Network Care Using a Human-Centered Design Sprint.

J Med Internet Res
Hopstaken JS, Koeneman M, Hooijer R, van Rijssel CC, van Voorthuizen T, Oort FA, Blanken CFJM, de Groot M, van Laarhoven CJHM, Stommel MWJ.   +9 more
europepmc   +1 more source